Headlines

AbbVie buys ImmunoGen for $10.1 billion, expanding cancer drug portfolio

AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.

Lumen Bioscience bags $5.5 million to develop needle-free vaccines

Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.

PlaqueTec recruits first ten patients in cardiovascular disease trial

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has received approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Atropos Health forms Life Science Advisory Board with pharma industry experts

A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.